CogniCurrent Icon

COGNICURRENT

A compact global news feed for the bigger picture.

βŒ•
Regions
Topics
Saved views:
Save your current filters to revisit or share.
4 stories
πŸ‡§πŸ‡· G1 (PT)
Life & Tech

New oral GLP-1 reduces more glucose and weight than semaglutide in phase 3 study; Orforgliprona increases weight loss by 73%

The experimental drug orforgliprona demonstrated greater glucose control and weight loss compared to oral semaglutide in a phase 3 study for type 2 diabetes treatment.

Feb 26 β€’ 16:48 UTC
πŸ‡§πŸ‡· Folha (PT)
National & Local

End of Ozempic patent could reduce price by up to 35%, says laboratory wanting to make generic

The expiration of the semaglutide patent in March is expected to lead to a price reduction of up to 35% for Ozempic, according to pharmaceutical company EMS, which is interested in producing a generic version.

Feb 25 β€’ 11:00 UTC
πŸ‡§πŸ‡· G1 (PT)
National & Local

Anvisa is set to decide next week on national versions of Ozempic

Brazil's National Health Surveillance Agency (Anvisa) is expected to announce its decision regarding the registration of national versions of semaglutide-based pens, essential for diabetes treatment, next week.

Feb 18 β€’ 11:15 UTC
πŸ‡§πŸ‡· Folha (PT)
Life & Tech

Mounjaro Rotation' trivializes the use of medications, say specialists

Experts warn that restaurant initiatives offering reduced portions for users of the medication semaglutide, branded as 'Mounjaro Rotation,' may trivialize its use and alter dining dynamics.

Feb 6 β€’ 18:19 UTC

Story in context

Loading Intelligence...

πŸ“‘

Select a report from the feed to view analysis and related coverage.